Related Experiment Video
Updated: Feb 18, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
miR-320a modulates cell growth and chemosensitivity via regulating ADAM10 in gastric cancer
Xiancai Ge1, Haiyan Cui2, Yanbing Zhou3
1Department of General Surgery, 401 Hospital of People's Liberation Army, Qingdao, Shandong 266000, P.R. China.
Abstract:
MicroRNAs (miRNAs) may function as tumor suppressor or onco‑miRNAs and have critical roles in the pathogenesis of gastric cancer (GC). The exact function and mechanism of miRNA (miR)‑320a in GC remains to be elucidated. The present study performed gain‑ and loss‑of‑function analyses by transfecting cells with mimics or inhibitors and subsequently performing colony formation, proliferation and cisplatin‑sensitivity assays. Additionally, in vivo xenograft models were also performed. Bioinformatics algorithms, luciferase reporter activity assay and western blotting were used to predict the potential target of miR‑320a. Additionally, the effect of knockdown or overexpression of ADAM metallopeptidase domain 10 (ADAM10) on cell growth and chemosensitivity was examined. The expression of miR‑320a and ADAM10 was also determined in primary tumors. The present study revealed that the expression of miR‑320a was reduced in GC cells and ectopic miR‑320a expression significantly inhibited cell growth in vitro and in vivo and enhanced the sensitivity of GC cells to cisplatin. ADAM10 was a direct target of miR‑320a in GC. Knockdown of ADAM10 attenuated the proliferative ability of GC cells, and increased the sensitivity of GC cells to cisplatin. The upregulated ADAM10 accelerated cell growth rate and reduced the cisplatin‑sensitivity of cells. Clinically, a significantly negative correlation was identified between the expression of miR‑320a and mRNA levels of ADAM10 in tumors. The findings of the present study suggested that miR‑320a may function as a tumor suppressor in GC progression and potential therapeutic strategies for GC may be based on the miR‑320a/ADAM10 axis.
Insights
MicroRNA-320a acts as a tumor suppressor in gastric cancer (GC) by inhibiting growth and enhancing cisplatin sensitivity. It targets ADAM10, suggesting a potential therapeutic axis for GC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNAs (miRNAs) play crucial roles in gastric cancer (GC) pathogenesis, acting as either tumor suppressors or oncogenes.
- The specific role and mechanism of microRNA (miR)-320a in GC are not fully understood.
- Gastric cancer remains a significant global health challenge, necessitating novel therapeutic targets.
Purpose of the Study:
- To elucidate the function and mechanism of miR-320a in gastric cancer.
- To identify the direct target of miR-320a in GC.
- To investigate the therapeutic potential of the miR-320a/ADAM10 axis in GC.
Main Methods:
- Gain- and loss-of-function analyses using miRNA mimics and inhibitors in GC cells.
- In vitro assays including colony formation, proliferation, and cisplatin-sensitivity tests.
- In vivo xenograft models, bioinformatics, luciferase reporter assays, western blotting, and analysis of primary tumor samples.
Main Results:
- miR-320a expression was significantly reduced in GC cells.
- Ectopic miR-320a expression inhibited GC cell growth (in vitro and in vivo) and increased cisplatin sensitivity.
- ADAM metallopeptidase domain 10 (ADAM10) was identified as a direct target of miR-320a; its knockdown mimicked miR-320a's tumor-suppressive effects.
- A negative correlation between miR-320a and ADAM10 expression was observed in GC tumors.
Conclusions:
- miR-320a functions as a tumor suppressor in gastric cancer progression.
- The miR-320a/ADAM10 axis represents a potential therapeutic target for gastric cancer.
- Modulating miR-320a or ADAM10 could offer novel treatment strategies for GC.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

